Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

Viral Infections, Non-HIV

Identifying and Interrupting Superspreading Events-Implications for Control of Severe Acute Respiratory Syndrome Coronavirus 2

Emerg Infect Dis.

Frieden TR, Lee CT

doi: 10.3201/eid2606.200495.

Viral Infections, Non-HIV

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients

Emerg Infect Dis.

Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL

doi: 10.3201/eid2607.200841.

Viral Infections, Non-HIV

Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020

Emerg Infect Dis.

Arima Y, Shimada T, Suzuki M, Suzuki T, Kobayashi Y, Tsuchihashi Y, Nakamura H, Matsumoto K, Takeda A, Kadokura K, Sato T, Yahata Y, Nakajima N, Tobiume M, Takayama I, Kageyama T, Saito S, Nao N, Matsui T, Sunagawa T, Hasegawa H, Ohnishi M, Wakita T

doi: 10.3201/eid2607.200994.

Viral Infections, Non-HIV

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States

Emerg Infect Dis.

Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden CR, Zhang J, Li Y, Uehara A, Wang H, Goldsmith C, Bullock HA, Wang L, Whitaker B, Lynch B, Gautam R, Schindewolf C, Lokugamage KG, Scharton D, Plante JA, Mirchandani D, Widen SG, Narayanan K, Makino S, Ksiazek TG, Plante KS, Weaver SC, Lindstrom S, Tong S, Menachery VD, Thornburg NJ

doi: 10.3201/eid2606.200516.

Viral Infections, Non-HIV

Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe

Emerg Infect Dis.

Olsen SJ, Chen MY, Liu YL, Witschi M, Ardoin A, Calba C, Mathieu P, Masserey V, Maraglino F, Marro S, Penttinen P, Robesyn E, Pukkila J, European COVID-19 Work Group.

doi: 10.3201/eid2607.200359.

Viral Infections, Non-HIV

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Clin Infect Dis.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D

doi: 10.1093/cid/ciaa237.

Viral Infections, Non-HIV

Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2

Emerg Infect Dis.

Waggoner JJ, Stittleburg V, Pond R, Saklawi Y, Sahoo MK, Babiker A, Hussaini L, Kraft CS, Pinsky BA, Anderson EJ, Rouphael N

doi: 10.3201/eid2607.201285.

Viral Infections, Non-HIV

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

N Engl J Med.

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH

doi: 10.1056/NEJMoa2016638.

Viral Infections, Non-HIV

Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020

Emerg Infect Dis.

Guo ZD, Wang ZY, Zhang SF, Li X, Li L, Li C, Cui Y, Fu RB, Dong YZ, Chi XY, Zhang MY, Liu K, Cao C, Liu B, Zhang K, Gao YW, Lu B, Chen W

doi: 10.3201/eid2607.200885.

Related content

Identifying and Interrupting Superspreading Events-Implications for Control of Severe Acute Respiratory Syndrome Coronavirus 2

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients

Severe Acute Respiratory Syndrome Coronavirus 2 Infection among Returnees to Japan from Wuhan, China, 2020

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease, United States

Early Introduction of Severe Acute Respiratory Syndrome Coronavirus 2 into Europe

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020